Please note: AABB reserves the right to make updates to this program.
Live Program Date: February 14, 2019 -
Master Program Number: 19EL-406 (see program format numbers below under Registration)
Educational Track: Scientific
Topic: Cellular Therapies
Intended Audience: Director, Donor Recruitment Staff, Hospitals, Hospital Blood Banks, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Research Scientists, Resident/Fellow, Scientists, Students (MD, MT, SBB), Technologists, Midwives
Teaching Level: Basic to Intermediate
Director/Moderator: Jennifer L. Chain, PhD, Science Officer for Cellular Therapies, Oklahoma Blood Institute, Oklahoma City, OK
Speakers: Kyle Cetrulo, Co-Founder & Chief Executive Officer, Auxocell; Co-Founder & President, Perinatal Stem Cell Society, Inc., Boston, MA; Ramon Coronado, MSc, PhD, Executive Director, Lester Smith Medical Research Institute; Rouzbeh R. Taghizadeh, PhD, Co-Founder & Chief Scientific Officer, AuxoCell; Co-Founder & Director, Perinatal Stem Cell Society; Sean Murphy, PhD, Assistant Professor, Wake Forest Institute for Regenerative Medicine, Co-Founder & Director, Perinatal Stem Cell Society
After participating in this educational activity, participants should be able to:
- Describe what perinatal tissues and cells are and the various ways that they are being manufactured.
- Explain how perinatal tissue and cells are being used in clinics and clinical trials.
- Discuss various sources methods and ethical issues around the sourcing of perinatal tissues and cells.
- Describe a new sourcing model and a new banking model.
This is a joint program between AABB and the Perinatal Stem Cell Society designed to increase awareness of the therapeutic potential of perinatal stem tissue and cell products. The program will cover:
- Introduction to Perinatal Tissues and Cell Products Industry Issues
Presenter: Kyle J. Cetrulo, Co-Founder & Chief Executive Officer, AuxoCell; Co-Founder & President, Perinatal Stem Cell Society
Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/wharton’s jelly, as well as placental blood and placental tissue. Perinatal stem cells are formed around the time of birth and are classified as adult stem cells but they really are more primitive than other adult stem cells and as such, have greater therapeutic potential. Today the field of perinatal tissue and stem cell products is exploding as many patients begin to benefit from increasing clinical availability of these products. But with every emerging field there are many challenges facing the industry that must be overcome in order to achieve the maximum benefit for patients in need. The presenter hopes to address some of the areas the Industry needs to focus on.
- Human Immunomodulatory Role of Perinatal Derived Cells
Presenter: Ramon Coronado, MSc, PhD, Executive Director, Lester Smith Medical Research Institute
During pregnancy, perinatal tissues have a fundamental immunoregulatory function. During this portion of the program, the presenter will present some of their studies related to the role of perinatal cells derived from different tissues and their adaptive and innate immunomodulation effects. The purpose of the studies is to leverage the immunomodulatory cell's mechanisms to further human therapies pertinent to autoimmune diseases and organ transplantation.
- Perinatal Mesenchymal Stem/Stromal Cell (MSC) Banking Technologies from Umbilical Cord Tissue
Presenter: Rouzbeh R. Taghizadeh, PhD, Co-Founder & Chief Scientific Officer, AuxoCell; Co-Founder & Director, Perinatal Stem Cell Society
The interest in processing, banking, and ultimate utility of cells derived from the human umbilical cord tissue has been growing, particularly over the past decade. This presentation will provide an introduction to the umbilical cord tissue and explore the current umbilical cord tissue processing methods to derive both native and non-native (ex vivo expanded) cellular products. Data will be presented exploring enzymatic and non-enzymatic (mechanical) processing methods, as well as the biological effects of enzymatic digestion on umbilical cord tissue processing.
- Amnion Membrane Derived Biomaterials for Skin Wound Treatment
Presenter: Sean Murphy, PhD, Assistant Professor, Wake Forest Institute for Regenerative Medicine; Co-Founder & Director, Perinatal Stem Cell Society
There is a need for effective wound treatments that retains the bioactivity of a cellular treatment, but without the high costs and complexities associated with manufacturing, storing and applying living biological products. This presentation will provide an overview of the development of an amnion membrane-derived hydrogel and a less-processed amnion product comprising a lyophilized amnion membrane powder. Data will be presented describing the wound healing properties of these amnion products using full thickness mouse and porcine skin wound models, and comparisons with commercially available amnion and non-amnion wound healing products.
| || ||
|Single Viewer: On-Demand||
|Group Viewing: On-Demand||
Continuing Education Credit
AABB designates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credits and credit types awarded for this program (live or on-demand) was determined by the program duration. For more information on each credit type please visit our
Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Kyle Cetrulo has been interested in Perinatal Stem Cells and non-profit organizations since 1998. As the former Director of the International Cord Blood Society (ICBS), Mr. Cetrulo organized the 5th and 6th International Congresses for the ICBS in 2002 and 2004, which had representatives from 23 countries participate in the meetings. In 2008, Mr. Cetrulo co-founded Auxocell Laboratories, Inc. (Auxocell). Auxocell achieved profitability in three years under his leadership and Mr. Cetrulo currently remains in the position of Chief Executive Officer at Auxocell. Editor of two editions of
Perinatal Stem Cells (Wiley Press, 2010 and 2013) and 2006 guest editor of the Stem Cell Reviews journal special edition focused on Perinatal Stem Cells, Mr. Cetrulo developed relationships with the world’s preeminent stem cell researchers working in the perinatal stem cell field. In 2013, Mr. Cetrulo along with his co-founders, decided to form the non-profit International Perinatal Stem Cell Society, Inc., in order to provide a platform for collaboration and the dissemination of knowledge and information about perinatal stem cells.
Dr. Ramon Coronado originated from Venezuela where he completed his BS in Polymer Engineering, then relocated to San Antonio, Texas in 2009. He continued his studies through the joint program at UTSA/UTHSCA in Biomedical Engineering, receiving his masters in 2011, followed by his PhD in 2016. In 2013, he founded Mobile Stem Care; a cell-based therapeutic company for animals. Following his success in animal care, Dr. Coronado was named Executive Director of the Lester Smith Medical Research Institute in 2015. There he continues to develop basic, translational, and clinical research programs that apply immune-regulatory mechanisms to improve treatment paradigms. In 2018, he was co-appointed Adjunct Assistant Professor in the Department of Obstetrics and Gynecology at Baylor School of Medicine. Dr. Coronado is currently researching immune-related mechanisms pertinent to fetal-maternal biology and developing cellular therapies to treat conditions applicable to transplant technologies, immune tolerance, and autoimmune diseases.
Dr. Sean Murphy received his PhD from Monash University, Melbourne, Australia and is currently an Assistant Professor at the Wake Forest Institute for Regenerative Medicine in North Carolina. His research focuses on the clinical application of perinatal cells and tissues for the treatment of injury and disease. Dr. Murphy has received numerous awards and fellowships, most notably an American Lung Association Senior Research Training Fellowship, and an American Australian Association Sir Keith Murdoch Fellowship. Dr. Murphy is Director/Secretary and Co-founder of the Perinatal Stem Cell Society, serves on the editorial board of multiple international journals and has recently published the book
Perinatal Stem Cells: Biology and Clinical Applications which provides a comprehensive overview of the therapeutic application of perinatal stem cells in both the clinical and preclinical settings.
Dr. Rouzbeh R. Taghizadeh has dedicated more than 15 years to bringing stem cell-based therapies to clinical practice. He earned his PhD in Stem Cell Bioengineering in 2006 from the Massachusetts Institute of Technology (MIT). In 2008, Dr. Taghizadeh co-founded Auxocell Laboratories, Inc. and currently serves as Auxocell’s Chief Scientific Officer. At Auxocell, Dr. Taghizadeh developed novel methods and technologies to establish the collection, processing, and banking of stem cells from the human umbilical cord for eventual utilization in stem cell-based therapies, regenerative medicine, and other clinical applications. Most notably, Dr. Taghizadeh and his team developed the novel single-use, disposable solid tissue processing system – the patented Auxocell Processing System (AC:Px™). Dr. Taghizadeh has contributed to numerous peer-reviewed publications, book chapters, and patents and is an editor of the
2nd edition of Perinatal Stem Cells.